• 1
    Jemal A,Siegel R,Ward E,Hao Y,Xu J,Murray T,Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 7196.
  • 2
    Pound CR,Partin AW,Eisenberger MA,Chan DW,Pearson JD,Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917.
  • 3
    Han M,Partin AW,Zahurak M,Piantadosi S,Epstein JI,Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 51723.
  • 4
    Warlick C,Trock BJ,Landis P,Epstein JI,Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006; 98: 3557.
  • 5
    Carter HB,Kettermann A,Warlick C,Metter EJ,Landis P,Walsh PC,Epstein JI. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007; 178: 235964.
  • 6
    Stephenson AJ,Scardino PT,Eastham JA,Bianco FJJr,Dotan ZA,DiBlasio CJ,Reuther A,Klein EA,Kattan MW. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 700512.
  • 7
    Makarov DV,Trock BJ,Humphreys EB,Mangold LA,Walsh PC,Epstein JI,Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095101.
  • 8
    Stephenson AJ,Smith A,Kattan MW,Satagopan J,Reuter VE,Scardino PT,Gerald WL. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005; 104: 2908.
  • 9
    DeMarzo AM,Nelson WG,Isaacs WB,Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361: 95564.
  • 10
    Nelson WG,De Marzo AM,Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 36681.
  • 11
    Rhodes DR,Sanda MG,Otte AP,Chinnaiyan AM,Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95: 6618.
  • 12
    Veltri RW. Molecular biology of serum biomarkers of prostate cancer. In: KirbyRS,PartinAW,FeneleyMR,ParsonsJK, eds. Prostate cancer: principles and practice. London: Taylor & Francis, 2006. 26984.
  • 13
    Tricoli JV,Schoenfeldt M,Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004; 10: 394353.
  • 14
    Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 2739.
  • 15
    Epstein JI,Allsbrook WCJr,Amin MB,Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 122842.
  • 16
    Carmichael MJ,Veltri RW,Partin AW,Miller MC,Walsh PC,Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995; 153: 101519.
  • 17
    Slamon DJ,Clark GM,Wong SG,Levin WJ,Ullrich A,McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 17782.
  • 18
    Slamon DJ,Godolphin W,Jones LA,Holt JA,Wong SG,Keith DE,Levin WJ,Stuart SG,Udove J,Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 70712.
  • 19
    Berchuck A,Kamel A,Whitaker R,Kerns B,Olt G,Kinney R,Soper JT,Dodge R,Clarke-Pearson DL,Marks P,McKenzie S,Yin S,Bast RCJr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 408791.
  • 20
    Veltri RW,Partin AW,Epstein JE,Marley GM,Miller CM,Singer DS,Patton KP,Criley SR,Coffey DS. Quantitative nuclear morphometry. Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem 1994; 19: 24958.
  • 21
    Savinainen KJ,Saramaki OR,Linja MJ,Bratt O,Tammela TL,Isola JJ,Visakorpi T. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002; 160: 33945.
  • 22
    Calvo BF,Levine AM,Marcos M,Collins QF,Iacocca MV,Caskey LS,Gregory CW,Lin Y,Whang YE,Earp HS,Mohler JL. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003; 9: 108797.
  • 23
    Reese DM,Small EJ,Magrane G,Waldman FM,Chew K,Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001; 116: 2349.
  • 24
    Signoretti S,Montironi R,Manola J,Altimari A,Tam C,Bubley G,Balk S,Thomas G,Kaplan I,Hlatky L,Hahnfeldt P,Kantoff P, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 191825.
  • 25
    Sadasivan R,Morgan R,Jennings S,Austenfeld M,Van Veldhuizen P,Stephens R,Noble M. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 1993; 150: 12631.
  • 26
    Schwartz S,Jr,Caceres C,Morote J,De Torres I,Rodriguez-Vallejo JM,Gonzalez J,Reventos J. Over-expression of epidermal growth factor receptor and c-erbB2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR. Int J Cancer 1998; 76: 4647.
  • 27
    Kuhn EJ,Kurnot RA,Sesterhenn IA,Chang EH,Moul JW. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993; 150: 142733.
  • 28
    Badalament RA,Miller MC,Peller PA,Young DC,Bahn DK,Kochie P,O'Dowd GJ,Veltri RW. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 1996; 156: 137580.
  • 29
    Veltri RW,O'Dowd GJ,Orozco R,Miller MC. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. Semin Urol oncol 1998; 16: 10617.
  • 30
    Hernes E,Fossa SD,Berner A,Otnes B,Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004; 90: 44954.
  • 31
    Edwards J,Traynor P,Munro AF,Pirret CF,Dunne B,Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 2006; 12: 12330.
  • 32
    Osman I,Mikhail M,Shuch B,Clute M,Cheli CD,Ghani F,Thiel RP,Taneja SS. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 2005; 174: 21747.
  • 33
    Domingo-Domenech J,Fernandez PL,Filella X,Martinez-Fernandez A,Molina R,Fernandez E,Alcaraz A,Codony J,Gascon P,Mellado B. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 2008; 19: 26975.
  • 34
    Andersen TI,Paus E,Nesland JM,McKenzie SJ,Borresen AL. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol (Stockholm, Sweden) 1995; 34: 499504.
  • 35
    Craft N,Shostak Y,Carey M,Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5: 2805.
  • 36
    Mellinghoff IK,Vivanco I,Kwon A,Tran C,Wongvipat J,Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004; 6: 51727.
  • 37
    Yeh S,Lin HK,Kang HY,Thin TH,Lin MF,Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999; 96: 545863.
  • 38
    Wen Y,Hu MC,Makino K,Spohn B,Bartholomeusz G,Yan DH,Hung MC. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 68415.
  • 39
    Casimiro M,Rodriguez O,Pootrakul L,Aventian M,Lushina N,Cromelin C,Ferzli G,Johnson K,Fricke S,Diba F,Kallakury B,Ohanyerenwa C, et al. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res 2007; 67: 436472.
  • 40
    Pianetti S,Arsura M,Romieu-Mourez R,Coffey RJ,Sonenshein GE. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 2001; 20: 128799.
  • 41
    Lessard L,Mes-Masson AM,Lamarre L,Wall L,Lattouf JB,Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003; 91: 41720.
  • 42
    Myers RB,Srivastava S,Oelschlager DK,Grizzle WE. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994; 86: 11405.
  • 43
    Qiu Y,Ravi L,Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998; 393: 835.
  • 44
    Canil CM,Moore MJ,Winquist E,Baetz T,Pollak M,Chi KN,Berry S,Ernst DS,Douglas L,Brundage M,Fisher B,McKenna A, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the national cancer institute of canada-clinical trials group. J Clin Oncol 2005; 23: 45560.
  • 45
    de Bono JS,Bellmunt J,Attard G,Droz JP,Miller K,Flechon A,Sternberg C,Parker C,Zugmaier G,Hersberger-Gimenez V,Cockey L,Mason M, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 25762.
  • 46
    Solit DB,Rosen N. Targeting HER2 in prostate cancer: where to next? J Clin Oncol 2007; 25: 2413.
  • 47
    Badalament RA,O'Toole RV,Young DC,Drago JR. DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 1991; 67: 301423.
  • 48
    Lorenzato M,Rey D,Durlach A,Bouttens D,Birembaut P,Staerman F. DNA image cytometry on biopsies can help the detection of localized Gleason 3+3 prostate cancers. J Urol 2004; 172: 131113.
  • 49
    Koss LG. Localized prostate cancer and DNA ploidy. JAMA 2005; 294: 1207; author reply 1207–8.
  • 50
    Adolfsson J,Ronstrom L,Hedlund PO,Lowhagen T,Carstensen J,Tribukait B. The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer. J Urol 1990; 144: 14046; discussion 1406–7.
  • 51
    Ahlgren G,Falkmer U,Gadaleanu V,Abrahamsson PA. Evaluation of DNA ploidy combined with a cytometric proliferation index of imprints from core needle biopsies in prostate cancer. Eur Urol 1999; 36: 31419.
  • 52
    Borre M,Hoyer M,Nerstrom B,Overgaard J. DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. Prostate 1998; 36: 2449.
  • 53
    Tribukait B. Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: clinical research and application. Eur Urol 1993; 23( Suppl 2): 6476.
  • 54
    Martinez-Jabaloyas JM,Ruiz-Cerda JL,Hernandez M,Jimenez A,Jimenez-Cruz F. Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation. Urology 2002; 59: 71520.
  • 55
    Sebo TJ,Cheville JC,Riehle DL,Lohse CM,Pankratz VS,Myers RP,Blute ML,Zincke H. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001; 91: 2196204.
  • 56
    Stamey TA. DNA ploidy status. Urology 1995; 45: 5635.
  • 57
    Thompson RH,Blute ML,Slezak JM,Bergstralh EJ,Leibovich BC. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol 2007; 178: 45963; discussion 63.